Know Thy R&D Enemy: The Key to Fighting Attrition

By and large, drug companies have sharply reduced their emphasis on novel targets and, they assume, pipeline risk. But detailed analysis shows that more important risk-reducers are the molecular approach (biologics targeting novel mechanisms fail less frequently than small molecules targeting precedented mechanisms) therapeutic approach (targeted is less risky than broad), therapeutic area, and stage of development.

Behzad Aghazadeh, Jeff Boschwitz, Charley Beever and Catherine Arnold

The drop in R&D productivity has been well documented and publicized. The Centre for Medicines Research , for example,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Leadership

More from In Vivo